Please refer to the following for major diseases and conditions applicable for proton therapy.
Just like body shape differs per each person, the disease progression and the conditions including subjective symptoms vary depending on each patient even with the same cancer type. Therefore, please be advised that the information provided here can give you only a rough idea. For more detailed information, please feel free to come to the Patient Support & Inquiry office and ask about your case.
At the Shizuoka Cancer Center, proton therapy is being provided for the diseases listed in the health insurance coverages and in the advanced medical care application (i.e., the ones meeting standard therapeutic criteria defined as the policy). There are the following common conditions applied for proton therapy.
No distant metastases
There is a difficulty for a localized treatment including a surgery.
Please see below for the applicable conditions per each disease. Even when the conditions are satisfied, there can still be the cases where proton therapy is not applicable due to the size or the location of the tumor.
With a full understanding on the state of tumor through preliminary examinations, a medical team led by the primary doctor discuss thoroughly about other options for treatment, including surgery, anti-cancer drug therapy and conventional radiation therapy, at the medical conference before deciding on whether the case is applicable for proton therapy.
|
Organs |
Applicable Diseases |
Medical Service Programs |
||
|
Diseases（※1） |
Applicable Conditions |
Health Insurance Coverage |
Advanced Medical Care A/B |
|
|
Pediatric |
Pediatric tumor |
Limited to localized solid malignant tumor |
〇 |
|
|
Brain |
Glioblastoma |
Glioblastoma with no disseminated spread |
|
A |
|
Astroglioma, oligodendrogliioma |
Glioma with no disseminated spread |
|||
|
Meningioma |
Almost unresectable or malignant meningioma, anaplastic meningioma |
|||
|
The other rare brain tumors |
Brain tumors classified in other tissue systems |
|||
|
Head and Neck Region |
Malignant tumors in the head and neck region |
Excluding squamous cancers in oral cavity and laryngophratynx |
〇 |
|
|
Squamous cancers in the head and neck region |
Cases where decrease in dose can’t be retained for organs at risk in conventional radiation therapy |
|
A |
|
|
Lung/ Mediastinum |
Localized lung cancer |
Primary lung cancer clinically staged Tis, T1-T4N0 （ExcludingT4 infiltrating adjacent organs） |
|
A |
|
Locally advanced non-small cell lung cancer |
Non-small cell lung cancer clinically staged TanyN1-3M0 or T4N0M0 (infiltrating adjacent organs） |
|||
|
Cancer in the trachea or bronchi |
Cases with no distant metastases |
|||
|
Mediastinum tumor |
Lung adenomatosis, thymic cancer, primary mediastinal lymphatic malignancy |
|||
|
Digestive Tract |
Localized colorectal cancer (postoperative recurrence) |
Cases where radical excision can’t be performed |
〇 |
|
|
Locally advanced esophageal cancer |
Staged I-III, and IV (localized esophageal cancer with no hematogenous metastases) |
|
A |
|
|
Liver/Bile Duct/Pancreas |
Hepatocellular cancer |
Cases with tumor size bigger than 4cm in long diameter, or where radical excision can’t be performed |
〇 |
|
|
Hepatocellular cancer |
Localized hepatocellular cancer (not covered by health insurance) |
|
A |
|
|
Hepatocellular cancer listed as an applicable case for clinical test |
Resectable primary, single, nodular type tumor; bigger than 3cm but below 12cm in maximum tumor diameter; staged cN0M0; aged 85 or younger; point 5 in Child-Pugh classification; PS 0-1 |
|
B |
|
|
Intrahepatic bile duct cancer |
Cases where radical excision can’t be performed |
〇 |
|
|
|
Biliary tract cancer |
Unresectable, or recurrent bile duct cancer (hilar bile duct cancer, extrahepatic bile duct caner) |
|
A |
|
|
Locally advanced pancreatic cancer |
Cases where radical excision can’t be performed |
〇 |
|
|
|
Urinary Organs |
Localized or locally advanced prostate gland cancer |
Excluding cases with metastases |
〇 |
|
|
Bladder cancer |
Primary bladder cancer clinically staged Ⅱ-Ⅲ |
|
A |
|
|
Kidney cancer |
Primary kidney cancer, unresectable for medical reasons, staged T1-4N0M0 |
|||
|
Others |
Bone and soft tissue tumor |
Localized, difficult for radical excision |
〇 |
|
|
Metastatic tumor in the lung |
Oligometastasis with 3 or less metastatic tumors |
|
A |
|
|
Metastatic tumor in the liver |
Oligometastasis with 3 or less metastatic tumors |
|||
|
※1
|
Some of the diseases are not applicable for proton therapy at the Shizuoka Cancer Center even if they are listed in the chart. |
|
For more detailed information, please make an inquiry. |
|
|
※2 |
Hepatocellular cancer which can be resected by a surgery, and which meets some other conditions will be applicable for the clinical test. |
|
When the case is applicable and the patient wishes to participate in the clinical test JCOG315C, the cost for the therapy will be deducted to 1,600,000 yen as it will be classified as proton therapy for advanced medical care B. |
Evaluation Test for Proton-beam Dose Tolerance in Nerves in Skull Base Chordoma and Chondrosarcoma
Evaluation Test of Prostatic Gland Displacement with a Rectum Deaerator Tube Set for Seriography of MRI
Multicenter Clinical Test for Safety Evaluation of Hypofractionation Proton Therapy for Hepatocellular Cancer
(All of the clinical tests above are conducted in the category of advanced medical care.)
